Although Orencia SC Enjoys a High Trial and Usage Rate One Year Post-Launch in Rheumatoid Arthritis, It Remains a Second-Line

  Although Orencia SC Enjoys a High Trial and Usage Rate One Year Post-Launch
  in Rheumatoid Arthritis, It Remains a Second-Line Therapy after TNF
  Inhibitors According to a Recent BioTrends Report

Business Wire

EXTON, Pa. -- December 17, 2012

BioTrends Research Group, one of the world’s leading research and advisory
firms for specialized biopharmaceutical issues, finds that after one full year
on the market, over 75 percent of surveyed rheumatologists have a high
familiarity with Bristol-Myers Squibb’s Orencia SC. Additionally, the vast
majority of surveyed physicians have prescribed Orencia SC, and both the
familiarity and usage represent significant increases versus the previous
three waves of this LaunchTrends: Orencia SC report. According to surveyed
physicians, the majority of Orencia SC patient starts were switched from other
agents, primarily the more established TNF inhibitors – Abbott’s Humira,
Pfizer/Amgen’s Enbrel and Janssen Biotech’s Remicade. This trend has steadily
increased over the four waves, while the percent switching from Orencia IV has
steadily decreased over the same time period.

In the next six months, surveyed rheumatologists expect to significantly
increase their use of Orencia SC, and this will drive up the overall Orencia
brand share. Further, doctors project that in the next six months Orencia SC’s
share will be almost equivalent to Orencia IV share. Physicians see little
difference between the IV and SC forms of Orencia relative to the most
important attributes for a biologic agent, and over three-quarters of surveyed
doctors prefer Orencia (co-stimulation) as their first line non-TNF biologic

“Orencia SC has done well in its first year of launch and seems to be growing
the overall Orencia brand,” said BioTrends Immunology Therapeutic Class
Director Paul Zimmerman. “However, the recent approval of Pfizer’s Xeljanz and
the expected approval of a subcutaneous form of Roche/Genentech’s Actemra will
offer rheumatologists even more therapy choices in an already crowded therapy
market for RA.”

LaunchTrends: Orencia SC is a series of four post-launch syndicated reports
designed to track the uptake of Bristol-Myers Squibb’s Orencia SC at one
month, three months, six months, and one year following launch. LaunchTrends
assesses trial and use of new products, barriers to use, reasons to use,
typical patient types, line of therapy, product perceptions, promotional
efforts/messages and product satisfaction. In this Wave 4 report, BioTrends
surveyed 102 rheumatologists and conducted in-depth qualitative interviews
with a subset of the respondents.

About BioTrends Research Group

BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please contact us at (610) 321-9400 or BioTrends is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group

    All company, brand, or product names contained in this document may be
                   trademarks of their respective holders.


BioTrends Research Group, LLC
Paul Zimmerman, 610-321-9427
Decision Resources Group
Christopher Comfort, 781-993-2597
Press spacebar to pause and continue. Press esc to stop.